Status:
RECRUITING
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Lead Sponsor:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Conditions:
Solid Tumors, Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treat...
Eligibility Criteria
Inclusion
- Male or female adults, aged greater than or equal to (≥) 18 years.
- Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma
- that is refractory to standard therapy known to provide clinical benefit for their condition OR
- have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR
- have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR
- for which no standard therapy is available
- Measurable disease according to RECIST version 1.1.
- Malignancy not currently amenable to surgical intervention.
- ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent.
- Other protocol defined inclusion criteria could apply
Exclusion
- Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.
- Other protocol defined exclusion criteria could apply
Key Trial Info
Start Date :
May 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06504368
Start Date
May 29 2024
End Date
December 31 2027
Last Update
November 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
NEXT Oncology
Irving, Texas, United States, 75039
2
Next Oncology
San Antonio, Texas, United States, 78229